Wei Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Chen has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Wei Tao
Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
14 shared publications - Jeffrey I. Zink
Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California 90095-1569, USA
11 shared publications - Chi-An Cheng
School of Pharmacy College of Medicine National Taiwan University Taipei 10050 Taiwan
8 shared publications - Chung-Yuan Mou
Department of Chemistry, National Taiwan University
6 shared publications - Na Kong
Zhejiang University
6 shared publications Yongjiang Li
6 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 6984-7000
Remodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis
- 8 August 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 6984-7000
Open AccessRemodeling macrophage efferocytosis and phenotype via targeted nanoimmunotherapy for atherosclerosis
- Open Access
- 4 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (10) , 8350-8371
Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis
Atherosclerotic macrophages predominantly exhibit a pro-inflammatory phenotype, driving chronic inflammatory and accelerating atherosclerotic progression. Interferon regulatory factor 5 (IRF5) is highly expressed in lesional macrophages within advanced atherosclerotic plaques, where it promotes the secretion of pro-inflammatory cytokines. However, current approaches lack an effective therapeutic strategy to specifically silence this gene in lesional macrophages for atherosclerosis treatment. This study aims to develop and evaluate a dual-targeted, siRNA-based nanotherapeutic platform that selectively acts on atherosclerosis-promoting genes in plaque macrophages, offering a potential strategy for treating atherosclerosis by reprogramming lesional macrophages. Here we designed and developed dual-targeted liposome-based nano-immunotherapeutics encapsulating small interfering RNA (siRNA) against IRF5 (siIRF5) to reprogram macrophage phenotypes within advanced plaques. In high-fat diet-fed ApoE-/- mice with advanced atherosclerotic plaques, dual-targeted siIRF5-loaded liposomes effectively accumulate within lesional macrophages, downregulate IRF5 expression, and promote anti-inflammatory macrophage polarization. Moreover, this siIRF5-based nanoimmunotherapy significantly reduces plaque burden and enhances plaque stability in two independent murine models of atherosclerosis. Furthermore, this siIRF5 nanoimmunotherapy exhibits biocompatibility even after long-term administration, underscoring its translational potential for clinical application in atherosclerosis treatment. This study introduces an innovative dual-targeted siRNA-based nanotherapeutic strategy that acts on atherosclerosis-promoting genes in plaque macrophages, offering a promising therapeutic avenue for atherosclerosis and other macrophage-driven inflammatory diseases.
- 4 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (10) , 8350-8371
Open AccessReprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis
Atherosclerotic macrophages predominantly exhibit a pro-inflammatory phenotype, driving chronic inflammatory and accelerating atherosclerotic progression. Interferon regulatory factor 5 (IRF5) is highly expressed in lesional macrophages within advanced atherosclerotic plaques, where it promotes the secretion of pro-inflammatory cytokines. However, current approaches lack an effective therapeutic strategy to specifically silence this gene in lesional macrophages for atherosclerosis treatment. This study aims to develop and evaluate a dual-targeted, siRNA-based nanotherapeutic platform that selectively acts on atherosclerosis-promoting genes in plaque macrophages, offering a potential strategy for treating atherosclerosis by reprogramming lesional macrophages. Here we designed and developed dual-targeted liposome-based nano-immunotherapeutics encapsulating small interfering RNA (siRNA) against IRF5 (siIRF5) to reprogram macrophage phenotypes within advanced plaques. In high-fat diet-fed ApoE-/- mice with advanced atherosclerotic plaques, dual-targeted siIRF5-loaded liposomes effectively accumulate within lesional macrophages, downregulate IRF5 expression, and promote anti-inflammatory macrophage polarization. Moreover, this siIRF5-based nanoimmunotherapy significantly reduces plaque burden and enhances plaque stability in two independent murine models of atherosclerosis. Furthermore, this siIRF5 nanoimmunotherapy exhibits biocompatibility even after long-term administration, underscoring its translational potential for clinical application in atherosclerosis treatment. This study introduces an innovative dual-targeted siRNA-based nanotherapeutic strategy that acts on atherosclerosis-promoting genes in plaque macrophages, offering a promising therapeutic avenue for atherosclerosis and other macrophage-driven inflammatory diseases.
- 2 December 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (22) , 1564-1581
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
BACKGROUND: Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment. METHODS: We developed an engineered small interfering RNA (siRNA) nanoparticle platform that can therapeutically manipulate lesional macrophages by inhibiting an overexpressed plaque-destabilizing macrophage molecule: IRF5 . RESULTS: IRF5 siRNA (siIRF5) nanoimmunotherapeutics were efficiently taken up by lesional macrophages, particularly Cd11c + and Trem2 hi macrophages, and enhanced their phagocytic clearance of apoptotic cells by efficiently silencing IRF5 expression within these macrophage subsets in atherosclerotic plaques. This resulted in remarkable therapeutic efficacy, as evidenced by reduction of necrotic core area and enhancement of plaque stability in 2 independent ApoE −/− murine models of atherosclerosis. Single-cell RNA sequencing analysis revealed that siIRF5 nanoimmunotherapeutics increased the proefferocytic receptors while decreasing the expression of proinflammatory genes associated with cytokine and chemokine pathways in lesional macrophages. CONCLUSIONS: These findings highlight the potential of siRNA nanoimmunotherapeutics for treating atherosclerosis and other diseases resulting from impaired efferocytosis in macrophages.
- 2 December 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 152 (22) , 1564-1581
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
BACKGROUND: Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment. METHODS: We developed an engineered small interfering RNA (siRNA) nanoparticle platform that can therapeutically manipulate lesional macrophages by inhibiting an overexpressed plaque-destabilizing macrophage molecule: IRF5 . RESULTS: IRF5 siRNA (siIRF5) nanoimmunotherapeutics were efficiently taken up by lesional macrophages, particularly Cd11c + and Trem2 hi macrophages, and enhanced their phagocytic clearance of apoptotic cells by efficiently silencing IRF5 expression within these macrophage subsets in atherosclerotic plaques. This resulted in remarkable therapeutic efficacy, as evidenced by reduction of necrotic core area and enhancement of plaque stability in 2 independent ApoE −/− murine models of atherosclerosis. Single-cell RNA sequencing analysis revealed that siIRF5 nanoimmunotherapeutics increased the proefferocytic receptors while decreasing the expression of proinflammatory genes associated with cytokine and chemokine pathways in lesional macrophages. CONCLUSIONS: These findings highlight the potential of siRNA nanoimmunotherapeutics for treating atherosclerosis and other diseases resulting from impaired efferocytosis in macrophages.
- Top Cited Papers
- 21 August 2025
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 125 (18) , 8835-8920
Therapeutic Hydrogels: Properties and Biomedical Applications
Hydrogels have emerged as versatile therapeutic platforms with immense potential for treating various diseases, due to their tunable properties and biocompatibility. Recent innovations, including injectable, self-assembling, and bioadhesive hydrogels, have broadened their biomedical applications, driven by advancements in materials chemistry. This review systematically examines the role of chemical principles in designing and customizing therapeutic hydrogels, with a focus on hydrogelation mechanisms, swelling ratios, mechanical properties, and biological interactions. By highlighting key studies in this field, this review explores how chemical chain modifications, cross-linking strategies, and cargo delivery systems have been tailored to achieve diverse functions, such as drug depots, wound dressings, antiadhesive barriers, and regenerative scaffolds. Addressing the gap in comprehensive analyses, this review underscores the integration of chemical design principles to optimize hydrogel properties for targeted therapies and discusses future opportunities to advance therapeutic hydrogel technology for a wide range of biomedical applications.
- 21 August 2025
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 125 (18) , 8835-8920
Top Cited PapersTherapeutic Hydrogels: Properties and Biomedical Applications
Hydrogels have emerged as versatile therapeutic platforms with immense potential for treating various diseases, due to their tunable properties and biocompatibility. Recent innovations, including injectable, self-assembling, and bioadhesive hydrogels, have broadened their biomedical applications, driven by advancements in materials chemistry. This review systematically examines the role of chemical principles in designing and customizing therapeutic hydrogels, with a focus on hydrogelation mechanisms, swelling ratios, mechanical properties, and biological interactions. By highlighting key studies in this field, this review explores how chemical chain modifications, cross-linking strategies, and cargo delivery systems have been tailored to achieve diverse functions, such as drug depots, wound dressings, antiadhesive barriers, and regenerative scaffolds. Addressing the gap in comprehensive analyses, this review underscores the integration of chemical design principles to optimize hydrogel properties for targeted therapies and discusses future opportunities to advance therapeutic hydrogel technology for a wide range of biomedical applications.
- 11 August 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (10) , 1526-1538
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles
Daily subcutaneous injections of recombinant interleukin-10 (IL-10) demonstrated encouraging but preliminary efficacy in certain tumour types during early phase clinical trials. However, these antitumour effects were not consistently replicated in larger trials, probably due to insufficient intratumoural recombinant IL-10 accumulation, which ultimately restricted clinical benefit. Here we show that intravenous injections of IL-10 messenger RNA (mRNA) nanoparticles (IL-10-mRNA@NPs) induce potent immune surveillance across diverse preclinical tumour models and mitigate systemic toxicities. In particular, IL-10-mRNA@NPs sustain in situ IL-10 production within tumours, promoting substantial infiltration and proliferation of cytotoxic T cells, activation and maturation of dendritic cells, and an augmented expression of major histocompatibility complex class I molecules in immunosuppressive orthotopic early stage hepatocellular carcinoma tumours. Moreover, in mice with orthotopic middle-to-late-stage hepatocellular carcinoma tumours, combining IL-10-mRNA@NPs with immune checkpoint blockades results in 43% of mice showing complete tumour eradication and a sixfold increase in median survival compared with mice treated with immune checkpoint blockades alone. Furthermore, this combination induces long-lasting antitumour immune memory, conferring 100% protection against tumour rechallenges. The intravenous IL-10-mRNA@NPs strategy may have potential to overcome the challenges associated with recombinant IL-10 in clinical trials across a broad spectrum of immunosuppressive tumours.
- 11 August 2025
- Published by Springer Nature in Nature Nanotechnology
- Vol. 20 (10) , 1526-1538
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles
Daily subcutaneous injections of recombinant interleukin-10 (IL-10) demonstrated encouraging but preliminary efficacy in certain tumour types during early phase clinical trials. However, these antitumour effects were not consistently replicated in larger trials, probably due to insufficient intratumoural recombinant IL-10 accumulation, which ultimately restricted clinical benefit. Here we show that intravenous injections of IL-10 messenger RNA (mRNA) nanoparticles (IL-10-mRNA@NPs) induce potent immune surveillance across diverse preclinical tumour models and mitigate systemic toxicities. In particular, IL-10-mRNA@NPs sustain in situ IL-10 production within tumours, promoting substantial infiltration and proliferation of cytotoxic T cells, activation and maturation of dendritic cells, and an augmented expression of major histocompatibility complex class I molecules in immunosuppressive orthotopic early stage hepatocellular carcinoma tumours. Moreover, in mice with orthotopic middle-to-late-stage hepatocellular carcinoma tumours, combining IL-10-mRNA@NPs with immune checkpoint blockades results in 43% of mice showing complete tumour eradication and a sixfold increase in median survival compared with mice treated with immune checkpoint blockades alone. Furthermore, this combination induces long-lasting antitumour immune memory, conferring 100% protection against tumour rechallenges. The intravenous IL-10-mRNA@NPs strategy may have potential to overcome the challenges associated with recombinant IL-10 in clinical trials across a broad spectrum of immunosuppressive tumours.
- Top Cited PapersOpen Access
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadw7191
Macrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy
Nanoparticle-based drug delivery systems hold promise for tumor therapy; however, they frequently encounter challenges such as low delivery efficiency and suboptimal efficacy. Engineered living cells can redirect drug delivery systems to effectively reach targeted sites. Here, we used living macrophages as vehicles, attaching them with GeS nanosheets (GeSNSs) carrying β-elemene for transport to tumor sites. GeSNSs act as efficient sonosensitizers, enhancing ultrasound-induced reactive oxygen species generation for treating 4T1 breast tumors. Notably, macrophage hitchhiking delivery of β-elemene–loaded GeSNSs not only achieves high accumulation in tumor regions and suppresses tumor growth under ultrasound treatment, but also effectively remodels the immunosuppressive tumor microenvironment by improving M1-like macrophage polarization and enhancing the populations of mature dendritic cells, CD4 + , and CD8 + lymphocytes, thereby facilitating enhanced sonodynamic chemoimmunotherapy. These findings underscore the potential of macrophage hitchhiking strategy for drug delivery and suggest broader applicability of engineered living materials–mediated delivery technologies in disease therapy.
- 23 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (21) , eadw7191
Top Cited PapersOpen AccessMacrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy
Nanoparticle-based drug delivery systems hold promise for tumor therapy; however, they frequently encounter challenges such as low delivery efficiency and suboptimal efficacy. Engineered living cells can redirect drug delivery systems to effectively reach targeted sites. Here, we used living macrophages as vehicles, attaching them with GeS nanosheets (GeSNSs) carrying β-elemene for transport to tumor sites. GeSNSs act as efficient sonosensitizers, enhancing ultrasound-induced reactive oxygen species generation for treating 4T1 breast tumors. Notably, macrophage hitchhiking delivery of β-elemene–loaded GeSNSs not only achieves high accumulation in tumor regions and suppresses tumor growth under ultrasound treatment, but also effectively remodels the immunosuppressive tumor microenvironment by improving M1-like macrophage polarization and enhancing the populations of mature dendritic cells, CD4 + , and CD8 + lymphocytes, thereby facilitating enhanced sonodynamic chemoimmunotherapy. These findings underscore the potential of macrophage hitchhiking strategy for drug delivery and suggest broader applicability of engineered living materials–mediated delivery technologies in disease therapy.
- 5 November 2024
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 22 (4) , 255-272
Nanomedicine-based strategies for the treatment of vein graft disease
Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40–50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms underlying vein graft disease, nanomedicine-based strategies offer promising opportunities to address this important unmet clinical need. In this Review, we provide deep insight into the latest developments in the rational design and applications of nanoparticles that have the potential to target specific cells during various pathophysiological stages of vein graft disease, including early endothelial dysfunction, intermediate intimal hyperplasia and late-stage accelerated atherosclerosis. Additionally, we underscore the convergence of nanofabricated biomaterials, with a particular focus on hydrogels, external graft support devices and cell-based therapies, alongside bypass surgery to improve local delivery efficiency and therapeutic efficacy. Finally, we provide a specific discussion on the considerations, challenges and novel perspectives for the future clinical translation of nanomedicine for the treatment of vein graft disease.
- 5 November 2024
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 22 (4) , 255-272
Nanomedicine-based strategies for the treatment of vein graft disease
Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40–50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms underlying vein graft disease, nanomedicine-based strategies offer promising opportunities to address this important unmet clinical need. In this Review, we provide deep insight into the latest developments in the rational design and applications of nanoparticles that have the potential to target specific cells during various pathophysiological stages of vein graft disease, including early endothelial dysfunction, intermediate intimal hyperplasia and late-stage accelerated atherosclerosis. Additionally, we underscore the convergence of nanofabricated biomaterials, with a particular focus on hydrogels, external graft support devices and cell-based therapies, alongside bypass surgery to improve local delivery efficiency and therapeutic efficacy. Finally, we provide a specific discussion on the considerations, challenges and novel perspectives for the future clinical translation of nanomedicine for the treatment of vein graft disease.
- Top Cited Papers
- 19 June 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (9) , 1386-1398
Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment
The buildup of plaques in atherosclerosis leads to cardiovascular events, with chronic unresolved inflammation and overproduction of reactive oxygen species (ROS) being major drivers of plaque progression. Nanotherapeutics that can resolve inflammation and scavenge ROS have the potential to treat atherosclerosis. Here we demonstrate the potential of black phosphorus nanosheets (BPNSs) as a therapeutic agent for the treatment of atherosclerosis. BPNSs can effectively scavenge a broad spectrum of ROS and suppress atherosclerosis-associated pro-inflammatory cytokine production in lesional macrophages. We also demonstrate ROS-responsive, targeted-peptide-modified BPNS-based carriers for the delivery of resolvin D1 (an inflammation-resolving lipid mediator) to lesional macrophages, which further boosts the anti-atherosclerotic efficacy. The targeted nanotherapeutics not only reduce plaque areas but also substantially improve plaque stability in high-fat-diet-fed apolipoprotein E-deficient mice. This study presents a therapeutic strategy against atherosclerosis, and highlights the potential of BPNS-based therapeutics to treat other inflammatory diseases.
- 19 June 2024
- Published by Springer Nature in Nature Nanotechnology
- Vol. 19 (9) , 1386-1398
Top Cited PapersResolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment
The buildup of plaques in atherosclerosis leads to cardiovascular events, with chronic unresolved inflammation and overproduction of reactive oxygen species (ROS) being major drivers of plaque progression. Nanotherapeutics that can resolve inflammation and scavenge ROS have the potential to treat atherosclerosis. Here we demonstrate the potential of black phosphorus nanosheets (BPNSs) as a therapeutic agent for the treatment of atherosclerosis. BPNSs can effectively scavenge a broad spectrum of ROS and suppress atherosclerosis-associated pro-inflammatory cytokine production in lesional macrophages. We also demonstrate ROS-responsive, targeted-peptide-modified BPNS-based carriers for the delivery of resolvin D1 (an inflammation-resolving lipid mediator) to lesional macrophages, which further boosts the anti-atherosclerotic efficacy. The targeted nanotherapeutics not only reduce plaque areas but also substantially improve plaque stability in high-fat-diet-fed apolipoprotein E-deficient mice. This study presents a therapeutic strategy against atherosclerosis, and highlights the potential of BPNS-based therapeutics to treat other inflammatory diseases.
- 30 April 2024
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 124 (10) , 6690-6692
Correction to Chemically Modified Platforms for Better RNA Therapeutics
- 30 April 2024
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 124 (10) , 6690-6692
Correction to Chemically Modified Platforms for Better RNA Therapeutics
- Open Access
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (15) , 7378-7386
Macrophage-modulating nanomedicine for cancer immunotherapy
We highlight the recent advances, discuss challenges, and propose future opportunities in nanomedicine-based strategies centered around macrophages for enhanced cancer immunotherapy.
- 5 March 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (15) , 7378-7386
Open AccessMacrophage-modulating nanomedicine for cancer immunotherapy
We highlight the recent advances, discuss challenges, and propose future opportunities in nanomedicine-based strategies centered around macrophages for enhanced cancer immunotherapy.